Clinical Trial Update: Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing bioequivalence of paroxetine IR tablets manufactured at two sites in healthy Chinese subjects; completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders

Drugs mentioned

• Paroxetine (Paroxetine hydrochloride)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anxiety Disorders | Phase 1 | Status: COMPLETED | Results posted: 2019-08-19